CYCN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 34.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Cyclerion Therapeutics Insider Trading History Chart

Cyclerion Therapeutics Share Price & Price History

^$1.70

▲ +0.17 (11.11%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Cyclerion Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/9/2023	Terrance Mcguire	Director	Sell	8	$3.40	$27.20	552

SEC Filings (Institutional Ownership Changes) for Cyclerion Therapeutics (NASDAQ:CYCN)

75.62% of Cyclerion Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cyclerion Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2025	Two Sigma Investments LP	13,293	$31K	0.0%	N/A	0.398%
8/15/2025	Tyndall Capital Partners L P	155,187	$0.45M	100.0%	-5.8%	4.646%
2/13/2025	Renaissance Technologies LLC	10,611	$34K	0.0%	N/A	0.392%
2/14/2024	Tyndall Capital Partners L P	164,429	$0.55M	100.0%	+11.3%	6.711%
11/14/2023	Tyndall Capital Partners L P	147,712	$0.51M	100.0%	N/A	6.129%
8/11/2023	Artal Group S.A.	138,955	$0.57M	0.0%	-95.0%	5.766%
5/9/2022	Trustcore Financial Services LLC	292,645	$0.33M	0.0%	+47.7%	0.674%
2/14/2022	Diametric Capital LP	100,480	$0.17M	0.1%	+43.9%	0.232%
2/10/2022	Acadian Asset Management LLC	249,792	$0.43M	0.0%	N/A	0.577%
11/16/2021	Two Sigma Advisers LP	647,700	$1.99M	0.0%	+98.4%	1.495%
11/16/2021	Two Sigma Investments LP	390,596	$1.20M	0.0%	+154.1%	0.902%
11/15/2021	Pura Vida Investments LLC	422,311	$1.30M	0.0%	-16.8%	0.975%
11/15/2021	Eversept Partners LP	371,955	$1.14M	0.1%	N/A	0.859%
11/15/2021	Franklin Resources Inc.	116,035	$0.36M	0.0%	N/A	0.268%
11/12/2021	Jump Financial LLC	52,000	$0.16M	0.0%	N/A	0.120%
11/12/2021	Geode Capital Management LLC	490,660	$1.51M	0.0%	+27.5%	1.134%
9/3/2021	Parametric Portfolio Associates LLC	12,596	$49K	0.0%	-52.0%	0.029%
8/17/2021	Millennium Management LLC	389,041	$1.52M	0.0%	N/A	0.899%
8/16/2021	State Street Corp	83,321	$0.33M	0.0%	-79.2%	0.193%
8/16/2021	Goldman Sachs Group Inc.	36,317	$0.14M	0.0%	-9.4%	0.084%

Data available starting January 2016

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.70

$1.49

$1.73

50 Day Range

MA: $1.92

$1.36

$2.55

52 Week Range

Now: $1.70

$1.28

$6.25

Volume

147,141 shs

Average Volume

1,057,117 shs

Market Capitalization

$6.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Who are the major institutional investors of Cyclerion Therapeutics?: Cyclerion Therapeutics' top institutional shareholders include:
Two Sigma Investments LP — 0.40%
Learn More about top institutional investors of Cyclerion Therapeutics stock.
Which major investors are buying Cyclerion Therapeutics stock?: In the previous quarter, CYCN stock was purchased by institutional investors including:
Two Sigma Investments LP